What Does the Research Say About Long-Term Gastroparesis Risk with Ozempic?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Wellness to Targeted Occupational Health Awareness

If you're taking Ozempic and experiencing persistent nausea, bloating, or abdominal pain, you may be wondering about the long-term risks. Medical research has increasingly focused on the link between GLP-1 receptor agonists and delayed gastric emptying, a condition known as gastroparesis. The evolution of public health communication has historically emphasized general wellness, but the rise of chronic medication use in the workplace now demands a closer look at specific drug-related side effects. This page reviews the published evidence on Ozempic and gastroparesis, helping you understand the current research landscape.

Bridging Occupational Health and Medical Evidence on Ozempic

Building on the need for updated health protocols, it is essential to examine the medical evidence linking Ozempic to gastroparesis. Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal (GI) complications are prominent, and a growing body of clinical evidence and case reports has linked GLP-1 agonists to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacology of Ozempic, mechanistic pathways connecting the drug to the condition, and risk considerations for affected patients in North Carolina, including statute of limitations and settlement-related factors.

Gastroparesis Clinical Presentation and Diagnosis

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can lead to malnutrition, dehydration, and significant impairment in quality of life. In the context of Ozempic use, patients may develop these symptoms during or after treatment, often requiring discontinuation of the drug and medical management.

Ozempic Pharmacology and Reported Adverse Effects

Ozempic works by mimicking the action of GLP-1, a hormone that stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This mechanism is central to its therapeutic effect but also underlies its GI side effects. According to the FDA-approved labeling, in placebo-controlled trials, GI adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to GI adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, GI adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional GI reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the slowing of gastric emptying is a known pharmacodynamic effect of GLP-1 agonists, and severe or persistent GI symptoms may indicate gastroparesis.

Mechanistic Pathways Linking Ozempic to Gastroparesis

The primary mechanism linking Ozempic to gastroparesis is its effect on gastric motility. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is dose-dependent and can become pathological in susceptible individuals, leading to gastroparesis. Additionally, Ozempic may cause vagal nerve dysfunction or alter enteric nervous system signaling, further impairing gastric emptying. Chronic use may lead to sustained gastric stasis, which can progress to symptomatic gastroparesis even after drug discontinuation.

Adequacy of Warnings Regarding Ozempic and Gastroparesis

The FDA-approved labeling for Ozempic includes warnings about GI adverse reactions but does not specifically mention gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be considered inadequate by some plaintiffs, as the drug's mechanism of action and clinical trial data suggest a plausible risk. Patients who developed gastroparesis after using Ozempic may argue that the manufacturer failed to provide sufficient warning about this potential complication.

Settlement-Related Considerations for Affected Patients

For patients in North Carolina who have developed gastroparesis after using Ozempic, settlement considerations depend on several factors. The statute of limitations for personal injury claims in North Carolina is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For product liability claims, including failure to warn, the same three-year limit applies. Patients must establish a causal link between Ozempic use and their gastroparesis, which may require medical expert testimony and documentation of the timeline between exposure and harm.

Timeline Between Exposure and Documented Harm

The onset of gastroparesis symptoms can vary. In clinical trials, GI adverse reactions occurred most frequently during dose escalation, suggesting that early exposure may trigger symptoms. However, some patients may develop gastroparesis after months or years of use. Documenting the timeline is critical for legal claims. Patients should maintain records of when they started Ozempic, dose changes, onset of GI symptoms, and any diagnostic tests confirming gastroparesis. This evidence helps establish that the harm occurred within the statute of limitations and is attributable to the drug. In summary, Ozempic use is associated with a high incidence of GI adverse reactions, and its mechanism of action can lead to gastroparesis. The adequacy of warnings is questionable, as the label does not specifically address this risk. Affected patients in North Carolina should be aware of the three-year statute of limitations and seek legal counsel to evaluate their claims. Settlement amounts may depend on the severity of harm, medical expenses, and the strength of evidence linking Ozempic to gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury and product liability claims, including failure to warn, is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Patients should consult an attorney to ensure their claim is filed within this timeframe.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism of action. While not explicitly listed as a side effect, clinical data show high rates of GI adverse reactions, and case reports link it to gastroparesis. Patients experiencing persistent GI symptoms should seek medical evaluation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Ozempic Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.